Recent acts of violence across the U.S. prompted officials at the University of Tennessee Health Science Center to host a show of unity on its Memphis campus. Students, faculty and staff joined together Nov. 8 to hear speeches reinforcing a message of acceptance and diversity. “Hate has no place at UTHSC,” read a banner signed… Read More
Dr. Patel oversees UTHSC’s Department of Dermatology, including all clinical, educational, and research activities.
Hundreds of students, faculty, and staff members signed banners with the words, “hate has no place at UTHSC” and “UTHSC is united against hate.” Thursday’s observance comes after several high-profile hate crimes in the country, including the recent mass shooting at a Jewish synagogue in Pennsylvania.
Our patient was a 70-year-old Caucasian male with a past medical history notable for hypertension, noninsulin-dependent diabetes, hypercholesterolemia and multiple myeloma previously treated with stem cell therapy. He presented with a two-day history of acute diplopia that was constant, binocular and exacerbated with right gaze. The patient also reported a new persistent right occipital headache.… Read More
New adventures are old hat for the recently appointed student representative to the University of Tennessee Board of Trustees. Kenneth Ian Packer, 29, is a Doctor of Nursing Practice student in the Certified Nurse Anesthetist program in the College of Nursing at the University of Tennessee Health Science Center. He has already done a four-year… Read More
Lupus nephritis recurrence rates in kidney transplant recipients declined over the past decade, compared with rates seen in earlier studies, according to a review of cases at the University of Tennessee Health Science Center (UTHSC).
Rhonda Ferguson-Wilkins, a family advocate counselor with the Shelby County Relative Caregiver Program at UTHSC, has been recognized for her good works in the community on WMC-TV’s “Bluff City Live.”
Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma… Read More
